The ZEUS trial enrolled adults with established ASCVD and chronic kidney disease to test whether monthly subcutaneous injections of ziltivekimab reduced major cardiovascular events. Investigators reported that the trial’s primary composite endpoint—heart attack, stroke or cardiovascular death—occurred in 561 participants assigned to ziltivekimab and 565 assigned to placebo. Overall mortality was also similar: 538 deaths in the ziltivekimab arm versus 542 in the placebo arm. These outcome rates produced a neutral result for the primary efficacy endpoint despite robust biomarker changes.
Blood markers of inflammation fell markedly with treatment. Compared to placebo, hs-CRP declined by 64% and interleukin-6 levels fell by 76% in patients receiving ziltivekimab. The study team observed that, although these biomarker reductions were substantial, they did not translate into a statistically significant reduction in the combined risk of heart attack, stroke or cardiovascular death in this trial population.
ZEUS enrolled 6,376 participants across 757 sites in 38 countries. The cohort’s average age was 69.4 years and 27.5% were women. Investigators described a very high-risk population: 92% had hypertension, nearly 66% had type 2 diabetes, and 42% had heart failure. Most participants (92.6%) were on cholesterol-lowering therapies at baseline. The study team noted that more than 6% of participants died during the trial—about double the mortality rate reported in contemporary atherosclerosis studies that excluded severe CKD—suggesting an advanced, high-burden disease state among enrollees.
Overall rates of side effects were similar between ziltivekimab and placebo groups. Investigators reported a higher rate of serious infections with ziltivekimab (20%) compared with placebo (18%), an expected safety signal for agents that suppress inflammatory pathways. The source did not provide additional detail on the nature or timing of those infections beyond these percentages.
Lead author Paul Ridker and colleagues interpreted the neutral clinical outcome in the context of prior trials that showed benefit from anti-inflammatory strategies. The investigators emphasized that earlier trials using an interleukin-1 inhibitor and low-dose colchicine reduced cardiovascular events in other populations, and they cautioned against overinterpreting a single neutral trial. The study team suggested that the advanced stage of ASCVD and CKD in ZEUS participants may have represented “too little, too late” for IL-6 inhibition to alter outcomes. As a result, investigators proposed studying IL-6 pathway inhibition in patients with less advanced disease and evaluating upstream approaches such as NLRP3 inflammasome inhibition. These specific research directions were described by the authors in the source; the article did not report results from those proposed approaches.
ZEUS was a double-blind, randomized, placebo-controlled phase III trial. Participants were randomly assigned to receive 15 mg of ziltivekimab or matching placebo by subcutaneous injection once monthly, in addition to usual care. Median treatment duration was 29.1 months and adherence to assigned treatment averaged 85.6% of scheduled doses. Investigators confirmed survival status for 99% of participants.
The authors listed a key limitation: study participants had both established ASCVD and clinically significant CKD, placing them at exceptionally high risk for events and death, which may limit generalizability to populations with earlier-stage disease. The source did not provide subgroup analyses that might identify specific patient subsets who benefited, nor did it present additional trial endpoints beyond those summarized here. The trial was funded by Novo Nordisk, and the ZEUS results were presented at the American Heart Association Scientific Sessions 2026 and simultaneously published in The New England Journal of Medicine.
The investigators concluded by reaffirming the clinical value of measuring inflammation in high-risk patients—"we can’t treat what we don’t know about," they wrote—and by calling for further randomized studies testing downstream IL-6 inhibition in less advanced disease and upstream NLRP3 targeting. The source did not report regulatory actions, changes to clinical practice guidelines, or the results of those future studies, and it emphasized that the findings should be interpreted in the context of the trial’s population and design.